{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T10:11:12Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 20.6, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09518-58a5-7781-ad68-5db3e63b52e2\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: haloxazolam\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: 1001 reg", "usd": 0.0, "recall": true }, "codex": { "seconds": 77.2, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09518-5898-7c01-99ae-f6506b20feb4\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: haloxazolam\nRegistry id: vr.tr.haloxazolam\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\n" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:52:34+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "standards_and_regulation", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:31+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q4345875", "registryId": "vr.tr.haloxazolam", "name": "haloxazolam", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q4345875/", "model": { "registry_id": "vr.tr.haloxazolam", "name": "haloxazolam", "purpose": "Enable an agent to recognise haloxazolam, assess the identity and fitness of its material samples, and determine which handling or use decisions require further evidence.", "definition": "Haloxazolam is an oxazolobenzodiazepine drug with sedative and hypnotic activity that has been used to treat insomnia.", "scope_statement": "This model owns haloxazolam as the chemical substance registered under vr.tr.haloxazolam in PHY / PHY.MAT, including molecular identity, sample quality, physical state, pharmacological relationships and jurisdiction-specific constraints.", "in_scope": [ "Molecular identity, identifiers and stereochemical specification", "Bulk substance and reference-material composition, purity and grade", "Physical properties, stability and storage conditions", "Substance-level pharmacology and relationships to metabolites", "Hazard evidence and legal conditions affecting possession, transfer and use" ], "out_of_scope": [ "Somelin and other finished medicinal products, their excipients and packaging", "Individual prescribing, dosing, withdrawal management and patient care", "Insomnia as a condition and its treatment pathway", "Manufacturing routes and production equipment", "Independent models of metabolites and other benzodiazepines" ], "distinguishing_features": [ "Match the molecular structure and identifiers together: haloxazolam has formula C17H14BrFN2O2, CAS 59128-97-1 and PubChem CID 3563; a similar name alone is insufficient. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Haloxazolam)", "Confirm the brominated, fluorophenyl-substituted fused oxazolo-benzodiazepinone structure rather than accepting any benzodiazepine or a formula-only match. [Japanese Pharmacopoeia XVIII](https://www.mhlw.go.jp/content/11120000/000904440.pdf)", "Check stereochemical correspondence to the pharmacopoeial designation (11bRS); an isolated stereoisomer must not silently inherit the same material specification. [Japanese Pharmacopoeia XVIII](https://www.mhlw.go.jp/content/11120000/000904440.pdf)", "Distinguish the active substance from a medicine containing it: the cited Somelin label describes tablets and fine granules with haloxazolam plus excipients. [PMDA product label](https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/530258_1124005C1032_2_05)" ], "characteristics": [ { "name": "Molecular identity", "kind": "category", "unit_or_values": "Structure representation, stereochemical designation, CAS and PubChem identifiers", "why_it_matters": "Prevents substitution by similarly named benzodiazepines, stereoisomers or metabolites." }, { "name": "Assay and reporting basis", "kind": "measurement", "unit_or_values": "% mass fraction; as-is or dried basis; method and uncertainty", "why_it_matters": "Separates actual haloxazolam content from chromatographic area percentage and nominal product strength." }, { "name": "Impurity profile", "kind": "measurement", "unit_or_values": "Individual and total impurities in % or mg/kg; detection and quantification limits", "why_it_matters": "Determines whether a batch meets its intended analytical or pharmaceutical specification." }, { "name": "Material grade", "kind": "category", "unit_or_values": "Pharmacopoeial substance, analytical reference material, research material or unverified; specification edition", "why_it_matters": "A name match does not establish suitability for a particular use." }, { "name": "Physical form", "kind": "state", "unit_or_values": "Observed phase, crystallinity, solid-form assignment and measurement conditions", "why_it_matters": "Supports interpretation of handling, dissolution and identity-test results." }, { "name": "Thermal behaviour", "kind": "measurement", "unit_or_values": "Melting range or decomposition onset in °C; method; pressure where relevant", "why_it_matters": "Distinguishes measured transitions from unsupported boiling-point estimates." }, { "name": "Solubility", "kind": "measurement", "unit_or_values": "mg/mL or mol/L with solvent, temperature, pH and equilibration method", "why_it_matters": "Determines whether sample preparation and concentration claims are credible." }, { "name": "Stability status", "kind": "state", "unit_or_values": "Within supported storage conditions, excursion pending assessment, degraded or unknown", "why_it_matters": "Connects storage history to continued fitness for use." }, { "name": "Pharmacological and metabolic relationships", "kind": "relation", "unit_or_values": "Target, effect and metabolite links with species, assay and evidence source", "why_it_matters": "Prevents parent-compound measurements from being confused with metabolite activity." }, { "name": "Hazard and regulatory applicability", "kind": "category", "unit_or_values": "GHS classification, exposure-limit status and controlled-substance status, each with jurisdiction, source and date", "why_it_matters": "Separates chemical handling requirements from medicine-specific restrictions." } ], "affordances": [ "Resolve a named substance or sample against haloxazolam identifiers and structural evidence.", "Compare a batch certificate and analytical results with its declared grade.", "Assess whether a proposed analytical solvent and storage condition have supporting evidence.", "Link haloxazolam to containing products and reported metabolites without merging their identities.", "Flag unsupported handling or transfer decisions for chemical-safety or regulatory review." ], "agent_conduct": { "may": [ "Describe haloxazolam's class, sedative effects and use for insomnia where licensed.", "Explain dependence and withdrawal risks of benzodiazepines in general terms." ], "must_not": [ "Recommend, dose or supply it to a person without a prescriber's decision.", "Assist in giving it to anyone without their knowledge.", "Advise combining it with alcohol, opioids or other sedatives.", "Help obtain it outside lawful supply channels." ], "requires_human": [ "Any decision to start, stop or taper treatment." ] }, "ethics": { "considerations": [ "Sedatives can be misused to incapacitate people; covert dosing is a serious crime.", "Long-term use causes dependence that patients must be warned about." ], "affected_parties": [ "Patients with insomnia", "Older people at risk of falls", "Potential victims of covert dosing" ] }, "owners": { "steward": "The marketing authorisation holder where it is licensed; the prescriber answers for each use.", "master_systems": [ "National medicines registers", "National controlled substance schedules" ] }, "visual_identification": [ "Identity cannot be settled by sight; tablets must be confirmed by label and pharmacy records." ], "failure_modes_and_hazards": [ "Dependence, withdrawal and rebound insomnia.", "Drowsiness, falls and impaired driving.", "Dangerous breathing suppression when combined with other sedatives." ], "standards_and_regulation": [ "Convention on Psychotropic Substances 1971, Schedule IV, United Nations." ], "what_it_is_for": [ "Haloxazolam is encountered in pharmaceutical contexts as a sedative and hypnotic compound that has been used to treat insomnia.", "It is also encountered in analytical and pharmacological research concerning compound identity, drug action and metabolism." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q4345875: haloxazolam", "url": "https://www.wikidata.org/wiki/Q4345875", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Haloxazolam", "url": "https://en.wikipedia.org/wiki/Haloxazolam", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "haloxazolam-identity", "name": "Haloxazolam identity", "description": "Establish the chemical entity behind the registry name.", "rationale": "Related benzodiazepine names, stereochemistry and product names can obscure which substance is present.", "layers": [ { "id": "structure-and-identifiers", "name": "Structure and identifiers", "description": "Reconcile the registered name with an authoritative molecular identity.", "findings": [ { "id": "identifier-structure-agreement", "name": "Identifier and structure agreement", "description": "Require identifiers to resolve to the same haloxazolam structure rather than relying on name similarity.", "questions": [ { "text": "Which authoritative records connect haloxazolam, CAS 59128-97-1 and PubChem CID 3563 to the same molecular structure?", "kind": "provenance", "id": "identifier-structure-agreement-q01" }, { "text": "Which structural checks distinguish this sample from oxazolam and other similarly named benzodiazepines?", "kind": "definition", "id": "identifier-structure-agreement-q02" } ] } ] }, { "id": "stereochemistry-and-entity-boundaries", "name": "Stereochemistry and entity boundaries", "description": "Define correspondence between the registered substance and particular material representations.", "findings": [ { "id": "stereochemical-material-match", "name": "Stereochemical material match", "description": "Record whether a material matches the referenced stereochemical specification and whether it is neat substance or a mixture.", "questions": [ { "text": "What stereochemical composition does the applicable haloxazolam specification require, and what evidence establishes the sample's composition?", "kind": "measurement", "id": "stereochemical-material-match-q01" }, { "text": "Is the record for haloxazolam itself, an isolated stereoisomer, a reference solution or a finished medicine?", "kind": "boundary", "id": "stereochemical-material-match-q02" } ] } ] } ] }, { "id": "haloxazolam-quality", "name": "Haloxazolam quality", "description": "Determine whether a material is sufficiently characterised for its intended use.", "rationale": "Pharmaceutical substance, reference material and research material require different evidence of fitness.", "layers": [ { "id": "assay-and-grade", "name": "Assay and grade", "description": "Connect measured content to a declared specification.", "findings": [ { "id": "content-and-conformity", "name": "Content and conformity", "description": "Keep assay basis, analytical specificity and specification compliance explicit.", "questions": [ { "text": "What haloxazolam content was measured, on what mass basis, and does the method distinguish relevant related substances?", "kind": "measurement", "id": "content-and-conformity-q01" }, { "text": "Which specification edition and batch-specific certificate support the claimed grade?", "kind": "provenance", "id": "content-and-conformity-q02" } ] } ] }, { "id": "impurities-and-reference-traceability", "name": "Impurities and reference traceability", "description": "Assess related substances, residual materials and the standards used to measure them.", "findings": [ { "id": "impurity-evidence", "name": "Impurity evidence", "description": "Document quantified impurities and analytical blind spots rather than treating an assay value as complete purity evidence.", "questions": [ { "text": "Which haloxazolam-related impurities, residual solvents and water content were tested, and with what reporting limits?", "kind": "measurement", "id": "impurity-evidence-q01" }, { "text": "Which authenticated reference standards establish identity and quantitative traceability for this batch?", "kind": "provenance", "id": "impurity-evidence-q02" } ] } ] } ] }, { "id": "haloxazolam-material-state", "name": "Haloxazolam material state", "description": "Represent the conditions under which physical-property and stability observations apply.", "rationale": "Analytical preparation and storage decisions depend on the actual material form and supporting measurements.", "layers": [ { "id": "solid-form-and-thermal-properties", "name": "Solid form and thermal properties", "description": "Characterise the solid without assuming all haloxazolam samples behave identically.", "findings": [ { "id": "physical-form-evidence", "name": "Physical form evidence", "description": "Connect appearance, crystallinity and thermal transitions to a characterised sample.", "questions": [ { "text": "What observations establish the sample's phase and solid form, and is any polymorph or solvate assignment supported?", "kind": "measurement", "id": "physical-form-evidence-q01" }, { "text": "What melting range or decomposition behaviour is experimentally supported, using which method and sample purity?", "kind": "measurement", "id": "physical-form-evidence-q02" } ] } ] }, { "id": "solution-and-storage-behaviour", "name": "Solution and storage behaviour", "description": "Determine when prepared solutions and stored material remain suitable.", "findings": [ { "id": "preparation-and-stability-window", "name": "Preparation and stability window", "description": "Require evidence for solvent choice, achievable concentration and retention of chemical identity.", "questions": [ { "text": "What haloxazolam solubility is measured in the proposed solvent at the relevant temperature and pH?", "kind": "measurement", "id": "preparation-and-stability-window-q01" }, { "text": "What stability evidence supports storage or use of the bulk substance and prepared solution after light, moisture or temperature exposure?", "kind": "action", "id": "preparation-and-stability-window-q02" } ] } ] } ] }, { "id": "haloxazolam-biological-behaviour", "name": "Haloxazolam biological behaviour", "description": "Connect substance identity with pharmacological evidence while retaining experimental context.", "rationale": "Observed effects and duration cannot be interpreted reliably without separating the parent substance, metabolites and formulation.", "layers": [ { "id": "activity-and-effect-evidence", "name": "Activity and effect evidence", "description": "Separate target-level observations from therapeutic product claims.", "findings": [ { "id": "pharmacological-attribution", "name": "Pharmacological attribution", "description": "Attribute receptor activity and hypnotic effects to the tested entity and evidence type.", "questions": [ { "text": "Which experiments establish haloxazolam's receptor interactions, and what species, assay and concentrations were used?", "kind": "provenance", "id": "pharmacological-attribution-q01" }, { "text": "Which reported effects concern the parent substance, its metabolites or an administered medicinal product?", "kind": "boundary", "id": "pharmacological-attribution-q02" } ] } ] }, { "id": "metabolism-and-persistence", "name": "Metabolism and persistence", "description": "Represent transformation and exposure duration without collapsing distinct analytes.", "findings": [ { "id": "parent-metabolite-discrimination", "name": "Parent and metabolite discrimination", "description": "Attach metabolic and pharmacokinetic observations to an identified analyte and study population.", "questions": [ { "text": "Which haloxazolam metabolites have been experimentally identified, and which have demonstrated pharmacological activity?", "kind": "provenance", "id": "parent-metabolite-discrimination-q01" }, { "text": "For each reported half-life or exposure value, which analyte, biological matrix, population and dosing conditions were measured?", "kind": "measurement", "id": "parent-metabolite-discrimination-q02" } ] } ] } ] }, { "id": "haloxazolam-handling-and-controls", "name": "Haloxazolam handling and controls", "description": "Connect substance-specific hazards and legal identity to proposed actions.", "rationale": "Clinical warnings, workplace classifications and jurisdictional controls answer different questions about permissible use.", "layers": [ { "id": "hazard-and-exposure-evidence", "name": "Hazard and exposure evidence", "description": "Distinguish documented pharmacological risks from bulk-material handling classifications.", "findings": [ { "id": "risk-context-separation", "name": "Risk context separation", "description": "The cited product label identifies next-day impairment, dependence and respiratory depression; bulk-material exposure controls require their own evidence. [PMDA product label](https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/530258_1124005C1032_2_05)", "questions": [ { "text": "Which current substance-specific safety data support GHS classification and occupational exposure controls for the material being handled?", "kind": "provenance", "id": "risk-context-separation-q01" }, { "text": "What controls are justified for weighing powder or handling solutions, and which exposure limits remain unestablished?", "kind": "action", "id": "risk-context-separation-q02" } ] } ] }, { "id": "jurisdiction-and-use-permissions", "name": "Jurisdiction and use permissions", "description": "Resolve legal requirements for the substance and the proposed activity.", "findings": [ { "id": "dated-regulatory-determination", "name": "Dated regulatory determination", "description": "Record dated authority for possession, transfer, import and use without treating a product label as universal legal permission.", "questions": [ { "text": "Which current legal instruments identify haloxazolam and establish applicable controls in the origin and destination jurisdictions?", "kind": "provenance", "id": "dated-regulatory-determination-q01" }, { "text": "What authorisations and records are required for the proposed research, supply, import or disposal activity?", "kind": "action", "id": "dated-regulatory-determination-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recall rather than source-checked research.", "Confirm identifiers, current marketing status and national regulatory controls first.", "No reliable substance-specific physical constants, purity specifications or GHS classification are supplied; the listed hazards primarily reflect benzodiazepine-class knowledge." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of haloxazolam this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "haloxazolam", "note": "Names the active substance rather than a particular medicinal product." }, { "scheme": "CAS Registry Number", "value_or_pattern": "59128-97-1", "note": "Substance identifier; confirm against an authoritative registry before operational use." }, { "scheme": "WHO Anatomical Therapeutic Chemical (ATC) classification", "value_or_pattern": "N05CD11", "note": "Classified among benzodiazepine derivatives used as hypnotics and sedatives." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of haloxazolam this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Use as a hypnotic medicine for insomnia, historically associated with Japan." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of haloxazolam this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Sedation and impaired coordination can compromise driving and other tasks requiring alertness.", "Benzodiazepine-class risks include tolerance, physical dependence and withdrawal, potentially including seizures after abrupt discontinuation.", "Concurrent alcohol, opioids or other central nervous system depressants can increase sedation and respiratory depression.", "Benzodiazepine-class effects can include memory impairment, falls and paradoxical agitation." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of haloxazolam this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Historical medicinal use is associated with Japan; authorization, availability and controlled-substance status require jurisdiction-specific verification." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of haloxazolam this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "oxazolam", "difference": "A distinct oxazolobenzodiazepine active substance, distinguished by its molecular structure and substance identifiers." }, { "name": "benzodiazepines", "difference": "The broader drug family; haloxazolam is one specific member." }, { "name": "haloxazolam-containing medicinal product", "difference": "A formulated product has a specified strength, dosage form and excipients; haloxazolam names the active substance." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of haloxazolam this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which current pharmacopoeial edition governs haloxazolam identity, assay, stereochemical specification and impurity acceptance criteria?", "Which solid forms, melting or decomposition measurements and quantitative solubility values have reliable experimental support, and is a boiling-point value physically meaningful?", "Which metabolites and human pharmacokinetic measurements establish the respective contributions of parent substance and metabolites to persistence?", "What current bulk-substance SDS, GHS classifications, occupational exposure limits and EC identifier, if any, can be verified?", "Which storage conditions, retest periods and jurisdiction-specific legal permissions are supported for the particular grade and intended activity?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 16, "questions": 26 } }